Fortrea Holdings Inc.

Fortrea Holdings Inc. is a leading global contract research organization (CRO) dedicated to advancing biopharmaceutical products and medical devices from concept to market. The company offers a comprehensive suite of development and consulting services across the entire clinical pharmacology and clinical development spectrum, catering to a diverse clientele of pharmaceutical, biotechnology, and medical device firms. Fortrea's service delivery models are designed for flexibility, encompassing full-service solutions, functional service provider arrangements, and hybrid structures to meet the unique needs of each client. Their expertise spans the management of Phase I-IV clinical trials, specialized clinical pharmacology studies, and strategic consulting. Demonstrating a commitment to innovation and quality, Fortrea engages in strategic collaborations, such as its partnership with Emery Pharma for rapid impurity testing of critical drug components like rifampin, ensuring compliance with stringent regulatory standards. Furthermore, collaborations with entities like SCT Cell Manufacturing s.r.o. aim to accelerate the development and patient accessibility of advanced therapies. Headquartered in Durham, North Carolina, Fortrea leverages its scientific acumen and operational excellence to navigate the complexities of drug and device development, positioning itself as a vital partner in bringing life-changing treatments to patients worldwide.